G2/M Checkpoint & Mitotic Fidelity Mapping Service for Cell Cycle
Creative Biolabs bridges the gap between cell cycle theory and drug discovery by mapping the G2/M "phospho-switch." We provide deep-tier analysis of mitotic commitment, identifying the "point of no return" for Wee1 or Myt1 (PKMYT1) inhibitors. Our platform precisely tracks the transition from G2 arrest to mitotic entry, ensuring compounds induce mitotic catastrophe rather than transient delays. This high-fidelity molecular evidence supports strategic decision-making and accelerates the development of potent anti-mitotic agents.
Why Map G2/M Fidelity in Drug Discovery?
Creative Biolabs identifies therapeutic vulnerabilities by mapping the AURKA-PLK1-PP6 pathway to detect "BRCAness" in BRCA-wildtype tumors, expanding PARP inhibitors (PARPi) eligibility. We analyze the BEG pathway to safeguard mitotic exit and cytokinesis, preventing chromosome shearing. Our platform exploits G1-deficient cancers through synthetic lethality, using Myt1 or Wee1 inhibitors to abrogate the G2/M checkpoint. By forcing unscheduled mitosis before DNA repair, we overcome resistance and drive profound apoptosis, delivering high-fidelity data for precision oncology.
Comprehensive Molecular Mapping
Creative Biolabs offers a multi-dimensional platform that goes beyond simple cell cycle distribution. We provide:
Synthetic Lethality Validation
Mapping interactions between G2/M inhibitors and specific genomic backgrounds (e.g., p53 or CCNE1 amplification) to identify responder populations.
Mitotic Exit Timer Analysis
Specialized assays to monitor the greatwall-ENSA-PP2A axis, ensuring that cytokinesis does not occur prematurely—a vital safety metric for anti-mitotic leads.
Checkpoint Recovery Profiling
Analyzing the AURKA-PLK1-PP6 axis to determine if cells can "slip" out of arrest, which often drives drug resistance in heterogeneous tumors.
Harness the Power of High-Resolution Mapping — Connect With Our Ph.D. Scientists Today
The Technical Workflow: A Precise Roadmap to Lead Validation
Our workflow is designed to provide maximum clarity and reproducibility for complex biopharmaceutical projects, ensuring every kinetic shift is accounted for.
Publication
This review synthesizes 15 years of research on the mitotic checkpoint complex (MCC), the key effector that safeguards accurate chromosome division. The MCC, comprising BUBR1, BUB3, MAD2, and CDC20, inhibits the APC/C ubiquitin ligase to prevent premature anaphase. The article clarifies longstanding misconceptions, details its assembly/disassembly dynamics, and integrates recent near-atomic structural insights, providing a comprehensive model for understanding this essential genomic stability mechanism.
Fig.1 Inhibition of APC/C by the mitotic checkpoint prevents premature chromosome segregation.1
Why Choose Us?
Creative Biolabs stands at the forefront of cell cycle research. Our unique advantage lies in our ability to map not just the presence of proteins, but the timing and location of their activation. We are one of the few global CROs capable of providing detailed analysis of the BEG (PP2A-B55/ENSA/Greatwall) pathway, which acts as the ultimate fidelity timer in mitosis. Our technical expertise is backed by published data demonstrating that dysregulated checkpoint recovery pathways significantly reduce DNA repair efficiency and increase chromosomal instability. By leveraging these insights, Creative Biolabs helps you turn complex biological hurdles into streamlined drug discovery milestones.
Experience the Precision of Creative Biolabs — Request a Comprehensive Project Quote
FAQs
Can this service identify why my compound is causing multi-nucleation?
Yes. Multi-nucleation often results from premature cytokinesis. Our BEG pathway mapping analyzes the "EG timer" to see if your drug is triggering cytokinesis before chromosome separation is complete.
Do you support non-standard cell lines or PDX-derived cells?
Absolutely. Creative Biolabs encourages clients to use the most clinically relevant models. We can optimize our sensors and proteomic protocols for almost any mammalian cell type, including primary patient samples.
How do you compare to standard flow cytometry?
While flow cytometry gives a "snapshot" of the population, our mapping service provides temporal kinetics and specific phosphorylation site analysis, offering a much deeper mechanistic view of the cell cycle.
Customer Review
-
Enhanced Mechanism Validation
Using Creative Biolabs' G2/M mapping in our research has significantly facilitated the validation of our Myt1 inhibitor. Their ability to distinguish between T14 and T15 phosphorylation on Cdk1 was a game-changer for our MoA study. - Dr. Sarah L***n -
Seamless Integration
Integrating their HRR efficiency assays with cell cycle kinetics allowed us to identify a 'BRCAness' signature in our p53-mutant melanoma lines. This facilitated our move into PARPi combination studies. - Dr. Hel**a K
Related Services
Kinesin Panel Screening Service
Creative Biolabs analyzes the kinesin superfamily (KIF), investigating ATP-driven transport and mitotic spindle assembly. We provide precise assays to target kinesin dysregulation in cancer and neurodegeneration.
Learn More →Cell-based Phospholipidosis Analysis Service
Creative Biolabs assesses drug-induced phospholipidosis using high-content analysis (HCA). Our dose-response assays deliver precise, reliable data to support safety evaluations and drug discovery.
Learn More →How to Contact Creative Biolabs
Creative Biolabs provides the world's most comprehensive mapping service for the G2/M checkpoint and mitotic fidelity. From the core Cdk1/Wee1 engine to the sophisticated Greatwall-ENSA-PP2A timer and AURKA-driven recovery pathways, we provide the molecular precision required to transform raw data into clinical leads.
For more information or to receive a custom project proposal, please reach out to our support team.
Reference
- Liu, S. T., and H. Zhang. "The mitotic checkpoint complex (MCC): looking back and forth after 15 years." AIMS Mol Sci 3.4 (2016): 597-634. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3934/molsci.2016.4.597
Download our brochure